
    
      A pilot phase will consist of a 3 subject safety run-in, followed by 20 subject randomized
      phase to evaluate influenza vaccine response at 1 week and 4 weeks post infusion of LMSCs.
      This will be followed by a double-blinded, randomized, placebo-controlled phase.
    
  